Abbott ARCHITECT B·R·A·H·M·S PCT Test

Description

Used in conjunction with other laboratory findings and clinical
assessments, the ARCHITECT B∙R∙A∙H∙M∙S PCT assay is intended for use
as an:

• Aid in the risk assessment of critically ill patients on their first day of intensive care unit (ICU) admission for progression to severe sepsis and septic shock
• Aid in assessing the cumulative 28-day risk of all-cause mortality for patients diagnosed with severe sepsis or septic shock in the ICU or when obtained in the emergency department or other medical wards
  prior to ICU admission, using a change in PCT level over time
• Aid in decision making on antibiotic therapy for patients with suspected or confirmed lower respiratory tract infections (LRTI) – defined as community-acquired pneumonia (CAP), acute bronchitis, and acute exacerbation of chronic obstructive pulmonary disease (AECOPD) – in an inpatient setting or an emergency department
• Aid in decision making on antibiotic discontinuation for patients with
  suspected or confirmed sepsis.

Reagents:

Microparticles: Tris-based buffer with protein (bovine) stabilizer, rat IgG, and Triton X-405. Minimum concentration: 0.06% solids. Preservatives: ProClin 950 and sodium azide.

Conjugate: Anti-PCT (mouse, monoclonal) acridinium-labeled conjugate in phosphate buffer with protein (bovine) stabilizer and Triton X-405. Minimum concentration: 270ng/mL. Preservatives: ProClin 950 and sodium azide.

Specifications

• Content And Storage: 2°C to 8°C Do not freeze
• Sample Type: Serum, plasma
• Type: PCT Reagent Kit
• For Use With (Application): Quantitative determination of PCT (Procalcitonin) in human serum and plasma on the automated ARCHITECT analyzer
• Includes: Microparticles: 1 x 8.6mL; Conjugate: 1 x 5.9mL
• pH: At 20 °C (68 °F): Microparticles: 7; Conjugate: 6.5
• Quantity: 100 Tests

For In Vitro Diagnostic Use